Shamkhalova M Sh, Abugova I A, Shishko P I, Dedov I I, Kozlov L V, Aleshkin V A, Rozina M N
Probl Endokrinol (Mosk). 1993 Sep-Oct;39(5):16-20.
Azathioprine immunosuppressive therapy prolongs remissions and stimulates residual beta-cell function, suppresses insulin antibody production, reduces the activity of the complement and CH50 components, reduces initially increased cellular immunity parameters (total T and B cell counts, T helper to T inductor ratio, and the count of DR carrier cells) in patients with newly detected insulin-dependent diabetes mellitus; this makes this drug effective at the first stages of the disease. When selecting patients for immunosuppressive therapy the following immunity parameters should be examined: complement status, total counts of T and B lymphocytes, T-helper-inductor/T-suppressor-cytotoxic immunoregulation index, DR carrier cell counts. Reduced levels thereof are a contraindication against immunosuppressant therapy. Male patients with insulin-dependent diabetes mellitus debut at the age of over 25 are particularly susceptible to immunosuppressive therapy with azathioprine.
硫唑嘌呤免疫抑制疗法可延长缓解期并刺激残余β细胞功能，抑制胰岛素抗体产生，降低补体和CH50成分的活性，降低新诊断的胰岛素依赖型糖尿病患者最初升高的细胞免疫参数（总T细胞和B细胞计数、辅助性T细胞与诱导性T细胞比值以及DR载体细胞计数）；这使得该药物在疾病的第一阶段有效。在选择接受免疫抑制治疗的患者时，应检查以下免疫参数：补体状态、T淋巴细胞和B淋巴细胞总数、辅助性T细胞-诱导细胞/抑制性T细胞-细胞毒性免疫调节指数、DR载体细胞计数。这些参数水平降低是免疫抑制治疗的禁忌证。25岁以上首次发病的男性胰岛素依赖型糖尿病患者对硫唑嘌呤免疫抑制治疗尤为敏感。
